NovaBay Pharmaceuticals, Inc.
NBY
$1.02
$0.088.50%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.83M | 4.74M | 7.12M | 9.75M | 9.56M |
| Total Other Revenue | -3.00K | 14.00K | 27.00K | 34.00K | 9.00K |
| Total Revenue | 2.83M | 4.75M | 7.15M | 9.78M | 9.57M |
| Cost of Revenue | 1.29M | 807.00K | 807.00K | 807.00K | 1.02M |
| Gross Profit | 1.54M | 1.50M | 1.50M | 1.50M | 1.08M |
| SG&A Expenses | 8.58M | 9.08M | 8.80M | 8.39M | 7.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.88M | 9.89M | 9.62M | 9.21M | 8.72M |
| Operating Income | -7.05M | -7.58M | -7.31M | -6.90M | -6.62M |
| Income Before Tax | -7.95M | -8.47M | -8.66M | -8.25M | -8.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.95 | -8.47 | -8.66 | -8.25 | -8.65 |
| Earnings from Discontinued Operations | 11.19M | 11.80M | 12.32M | 1.03M | -1.47M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.24M | 3.32M | 3.66M | -7.22M | -10.12M |
| EBIT | -7.05M | -7.58M | -7.31M | -6.90M | -6.62M |
| EBITDA | -7.04M | -7.57M | -7.29M | -6.87M | -6.58M |
| EPS Basic | 0.74 | -0.96 | -2.00 | -33.39 | -79.77 |
| Normalized Basic EPS | -0.77 | -1.63 | -2.54 | -17.79 | -23.14 |
| EPS Diluted | 0.74 | -0.96 | -2.00 | -33.40 | -79.78 |
| Normalized Diluted EPS | -0.76 | -1.63 | -2.53 | -17.79 | -23.14 |
| Average Basic Shares Outstanding | 25.00M | 20.28M | 15.61M | 10.43M | 2.63M |
| Average Diluted Shares Outstanding | 25.10M | 20.38M | 15.72M | 10.43M | 2.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 148.47% | -- | -- | -- | -- |